Metastatic Renal Cancer
13
4
4
2
Key Insights
Highlights
Success Rate
29% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
38.5%
5 terminated out of 13 trials
28.6%
-57.9% vs benchmark
15%
2 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (13)
CAIX PET/ CT Guided Radiation Therapy in CcRCC.
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
Lu-177 PSMA Treatment in Cell Renal Carcinoma
SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer
Measuring Oncological Value of Exercise and Statin
Ketogenic Diet for Patients Receiving Treatment for Metastatic Renal Cell Carcinoma
Everolimus Modulation of Anti-tumor T CD4 Immune Responses
Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
Safety and Compliance of Renal Cancer Patients Treated by Non-IV Drugs
Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma
PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes